Loyal Dog Longevity Drug: What We Know So Far

After losing Cooper at 9, I’ve spent years reading every longevity study I can find—which is why I’m cautiously optimistic about Loyal’s dog longevity drug. The FDA just gave conditional approval to LOY-001, making it the first drug ever approved to extend healthy lifespan in dogs, though it won’t hit the market until late 2026 at the earliest.

If you’re like me and you’d do anything for a few more good years with your dog, here’s what the science actually says—and what we still don’t know.

What Is the Loyal Dog Longevity Drug?

Loyal is a San Francisco-based veterinary company developing two drugs specifically designed to extend canine lifespan. Not just make older dogs more comfortable (though that’s valuable too), but actually slow biological aging and add healthy years to their lives.

The lead candidate is LOY-001, an injectable medication for large and giant breed dogs. In May 2023, the FDA granted it conditional approval based on reasonable expectation of effectiveness—the first aging drug to reach this milestone in any species. Full approval requires completing efficacy studies, expected by late 2026 or early 2027.

Their second drug, LOY-002, is a daily pill for all dog sizes currently in clinical trials.

The Science Behind LOY-001: Why Large Dogs Age Faster

Here’s what broke my heart when I first learned it: a Chihuahua can live 18 years, but a Great Dane averages just 7-8. The size-lifespan relationship in dogs is the opposite of what we see across species (elephants outlive mice), which tells us something breed-specific is happening.

Loyal’s research points to IGF-1 (insulin-like growth factor 1) as a key culprit. Large breed dogs have chronically elevated IGF-1 levels, which drives their rapid growth but also accelerates aging. Studies in mice, worms, and even humans show that lower IGF-1 is associated with longer lifespans.

LOY-001 works by reducing IGF-1 in adult dogs after they’ve finished growing. The goal is to slow cellular aging without affecting bone structure or muscle mass—since the dog is already full-grown.

What the Early Data Shows

Loyal hasn’t published peer-reviewed longevity data yet (that’s what the conditional approval trials are for), but their safety studies showed:

• Significant reduction in IGF-1 levels in treated dogs
• No adverse effects on mobility, body condition, or organ function
• Single injection provides sustained IGF-1 suppression for 3-6 months
• Well-tolerated across multiple large breed types

The FDA wouldn’t have granted conditional approval without reasonable expectation this will work. But “reasonable expectation” isn’t the same as proven results in a multi-year lifespan trial.

LOY-002: The Daily Pill for All Dogs

While LOY-001 targets the size-specific aging problem in large breeds, LOY-002 takes a different approach that could work for dogs of any size.

LOY-002 addresses age-related metabolic changes that happen in all dogs as they get older. Loyal describes it as targeting “fundamental aging pathways,” though they haven’t disclosed the exact mechanism publicly. It’s administered as a daily pill, similar to how you’d give a daily joint supplement.

This drug is earlier in development—still in clinical trials as of 2026—so we’re likely 2-3 years away from potential approval.

Which Dogs Could Benefit From LOY-001?

LOY-001 is specifically designed for dogs weighing over 40 pounds. Loyal’s initial focus is on breeds with the shortest average lifespans:

Breed Category	Average Lifespan	Potential Benefit
Giant breeds (Great Dane, Mastiff, Irish Wolfhound)	6-8 years	Highest potential impact; may add 1-2+ years
Large breeds (Golden Retriever, German Shepherd, Rottweiler)	10-12 years	Moderate potential; targeted reduction in IGF-1
Medium breeds (Border Collie, Cocker Spaniel)	12-14 years	Lower priority; already longer-lived
Small/toy breeds	14-18 years	Not indicated; LOY-002 may be more appropriate

The drug is intended to start in middle age, after growth plates have closed but before significant age-related decline begins. For most large breeds, that’s around 4-6 years old.

Timeline: When Will LOY-001 Be Available?

This is where managing expectations matters. Conditional approval means Loyal can market the drug once they complete manufacturing and final efficacy studies. The company has indicated late 2026 or 2027 for commercial availability.

What needs to happen first:

1. Complete multi-year lifespan trials – These take time because you’re literally measuring how long dogs live
2. Scale up manufacturing – Going from research batches to commercial production
3. Submit efficacy data to FDA – Convert conditional approval to full approval
4. Establish distribution through veterinary clinics – This will be prescription-only

My best guess? If you have a 3-year-old Great Dane today, LOY-001 might be available by the time they’re 5-6, which is still within the ideal treatment window.

Cost and Access: What to Expect

Loyal hasn’t announced pricing yet, but we can make educated guesses based on comparable veterinary biologics. Drugs requiring specialized manufacturing and offering unique benefits typically run $100-$300 per dose.

Since LOY-001 is injected every 3-6 months, annual costs could range from $400-$1,200. That’s in the ballpark of what people already spend on preventative care and supplements for large breed dogs.

The drug will require a prescription and veterinary administration, similar to vaccines or injectable arthritis treatments.

What We Still Don’t Know

I want to be honest about the gaps in our knowledge, because I learned with Cooper that false hope is worse than uncertainty.

We don’t know the actual lifespan extension yet. Loyal’s models suggest 1-3 additional years for giant breeds, but models aren’t reality. The ongoing trials will tell us.

We don’t know long-term safety over 5+ years. The safety data is solid for the trial duration, but widespread use over a decade will reveal rare side effects if they exist.

We don’t know how it interacts with breed-specific diseases. If your Bernese Mountain Dog is predisposed to cancer, will lowering IGF-1 help, hurt, or have no effect? We need more data.

We don’t know if starting earlier is better. Is there an optimal age to start treatment? Does beginning at age 4 vs. age 6 make a difference?

What You Can Do Right Now

While we wait for LOY-001 to become available, the fundamentals still matter more than any future drug:

• Maintain lean body condition – Obesity is the single biggest controllable factor reducing lifespan in dogs. Studies show lean dogs live 1.8 years longer than overweight littermates.
• Prioritize dental health – Chronic dental disease drives systemic inflammation. Regular brushing and dental chews make a difference.
• Keep them moving – Age-appropriate exercise maintains muscle mass and metabolic health. For large breeds, low-impact activities protect joints.
• Catch problems early – Annual bloodwork starting at age 5-6 can detect issues before symptoms appear. This is how I wish I’d found Cooper’s cancer.

If you have a large or giant breed dog, talk to your vet about Loyal’s timeline. Some clinics may offer enrollment in clinical trials or early access programs.

The Bigger Picture: What This Means for Dogs

Whether LOY-001 delivers 1 extra year or 3, the FDA approval is a watershed moment. It’s the first time a regulatory agency has recognized aging itself as something we can treat, not just accept.

This opens the door for more research into canine longevity. Other companies are developing aging interventions. Academic researchers now have a framework for approval. The field is moving.

For those of us who’ve lost dogs too young, that matters. Cooper died at 9 from oral melanoma I didn’t catch in time. If a longevity drug had given me even one more year to notice the signs, to get earlier treatment, to have more time—I’d have taken it.

That’s what this is really about: more time with the dogs we love, while they’re still feeling good.

Frequently Asked Questions

Is the Loyal dog longevity drug FDA approved?

LOY-001 received FDA conditional approval in May 2023, the first aging drug ever to reach this milestone. Conditional approval means the FDA has reasonable expectation it will work based on preliminary data, but full approval requires completing multi-year efficacy trials. The drug isn’t commercially available yet—expected late 2026 or 2027.

How much will LOY-001 cost?

Loyal hasn’t announced pricing yet. Based on comparable veterinary biologics, expect $100-$300 per injection, administered every 3-6 months. Annual costs could range from $400-$1,200, similar to what many owners already spend on preventative care for large breed dogs.

Can small dogs take the Loyal longevity drug?

LOY-001 is specifically designed for dogs over 40 pounds and targets the elevated IGF-1 levels that cause large breeds to age faster. Small dogs don’t have this problem—they already live 14-18 years on average. Loyal’s second drug, LOY-002, is being developed for dogs of all sizes but is still in clinical trials.

What breeds benefit most from LOY-001?

Giant breeds with the shortest lifespans stand to benefit most: Great Danes, Mastiffs, Irish Wolfhounds, Saint Bernards, and Bernese Mountain Dogs (average 6-8 years). Large breeds like Golden Retrievers, German Shepherds, and Rottweilers (10-12 year average) may also see lifespan extension, though likely less dramatic.

Are there side effects to the Loyal dog drug?

Safety studies so far show LOY-001 is well-tolerated with no adverse effects on mobility, body condition, or organ function. However, we don’t have long-term data over 5+ years of continuous use. As with any new drug, rare side effects may emerge during widespread use. Your vet will monitor your dog during treatment.